Tonix’s development portfolio is focused on central nervous system disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two statistically significant Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress disorder (ASD). Our pipeline is also comprised of immunology, rare disease, and infectious disease product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Our rare disease portfolio includes therapeutics to treat rare genetic conditions. Tonix’s infectious disease portfolio includes a live virus vaccine platform.